| Not Yet Recruiting | This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autol NCT07412405 | GUSTAVO SALGUERO | N/A |
| Not Yet Recruiting | Long-term Study to Evaluate Safety and Persistence of GF-CART01 NCT06985576 | GenomeFrontier Therapeutics TW Co., Ltd. | — |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma NCT07360288 | TICAROS Co., Ltd. | Phase 2 |
| Recruiting | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946 | LTZ Therapeutics, Inc. | Phase 1 |
| Recruiting | A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies NCT07154823 | Tempus AI | — |
| Not Yet Recruiting | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma NCT07168291 | First Affiliated Hospital Xi'an Jiaotong University | EARLY_Phase 1 |
| Recruiting | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma NCT07077512 | Sun Yat-sen University | Phase 2 |
| Recruiting | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118 | Health Institutes of Turkey | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relap NCT06703892 | GenomeFrontier Therapeutics TW Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatme NCT06757894 | Sun Yat-sen University | Phase 2 |
| Recruiting | Zanubrutinib Combined With G-CVP in Previously Untreated FL NCT06959732 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Not Yet Recruiting | The Microbiome in Blood Cancer and HLH NCT06734624 | University of Nottingham | — |
| Recruiting | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL NCT06526793 | AstraZeneca | Phase 2 |
| Recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Asse NCT06191744 | Genmab | Phase 3 |
| Recruiting | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combin NCT06091254 | Regeneron Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works C NCT06097364 | Regeneron Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicul NCT05888493 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011 | iOMEDICO AG | — |
| Terminated | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma NCT05720052 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Withdrawn | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphom NCT04796922 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Asse NCT05409066 | Genmab | Phase 3 |
| Recruiting | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022 | Nurix Therapeutics, Inc. | Phase 1 |
| Terminated | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) NCT04745832 | MEI Pharma, Inc. | Phase 3 |
| Recruiting | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137 | Nurix Therapeutics, Inc. | Phase 1 |
| Unknown | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies NCT04767308 | Huazhong University of Science and Technology | EARLY_Phase 1 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Unknown | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZ NCT04431089 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 |
| Completed | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715 | Epizyme, Inc. | Phase 1 |
| Active Not Recruiting | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) NCT04049513 | Malaghan Institute of Medical Research | Phase 1 |
| Terminated | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or Mor NCT03768505 | MEI Pharma, Inc. | Phase 2 |
| Recruiting | REal World Data in LYmphoma and Survival in Adults NCT03869619 | Hospices Civils de Lyon | — |
| Terminated | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Dif NCT03571828 | Amgen | Phase 1 |
| Terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115 | MEI Pharma, Inc. | Phase 1 |
| Recruiting | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and NCT03460977 | Pfizer | Phase 1 |
| Unknown | Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 NCT03265158 | Royal Marsden NHS Foundation Trust | — |
| Terminated | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma NCT02914938 | MEI Pharma, Inc. | Phase 1 |
| Completed | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated NCT02875548 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |